Halozyme Therapeutics | HALO - Assets


Halozyme Therapeutics reported $2.67B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amarin USD 645.76M 25.01M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Baxter International USD 19.85B 209M Mar/2026
Cara Therapeutics USD 32.07M 6.95M Dec/2025
Cytokinetics USD 1.27B 151.06M Mar/2026
DBV Technologies USD 233.72M 123.22M Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
MannKind USD 744.4M 47.78M Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Pfizer USD 207.62B 542M Mar/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
United Therapeutics USD 6.71B 1.17B Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025